Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Introducing artificial intelligence for IVF directly at the point of care, revolutionizing the influence of extensive image and text data on business insights in reproductive medicine. We have gathered a team of the foremost specialists in artificial intelligence, IVF lab quality control/assurance, and digital technology solutions to develop this innovative platform, which boasts the largest open-source image database dedicated to embryology and andrology competency assessment globally. ART Compass emerges as the state-of-the-art IVF Lab Information Management System (LIMS), enhancing IVF lab quality management through artificial intelligence, all accessible via a user-friendly smartphone app. This platform allows for the evaluation of embryology and andrology competency assessments, as well as supports clinical decision-making in these fields. Users can also access annual procedure evaluation documentation, record new training for procedures, and onboard new staff seamlessly. Furthermore, it enables tracking of pregnancy outcomes for each IVF cycle while providing all necessary statistics. In addition, it facilitates management of patient cryostorage inventory and efficiently delivers preimplantation genetic testing results to physicians, ensuring a comprehensive approach to reproductive health. Ultimately, ART Compass is not just a tool; it represents a significant advancement in how IVF labs can operate and improve patient care.
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
Free
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
ART Compass
Founded
2018
Country
United States
Website
artcompass.io
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/